The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap ...

randomly assigned 1:1 to transurethral resection of bladder tumor (TURBT) or mpMRI-staged care between May 31, 2018, and December 31, 2021. Participants were stratified by sex, age (less than 75 ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder ... following transurethral resection of bladder ...

The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...

Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder cancer (MIBC), according ...

ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...

In bladder cancer, the majority of published data available ... 39 In a later, larger study of 82 patients with NMIBC who were treated with transurethral resection and immunotherapy, tumor-informed ...

Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the ...